MGI a leader in life science innovation, proudly announces the inauguration of its new European headquarters in Berlin, Germany. This strategic expansion aims to enhance support for the life science community across the region.

State-of-the-Art Facility

Located near the Berlin Brandenburg Airport, the new headquarters spans over 600 square meters and features MGI’s latest products and technologies. The facility includes a Customer Experience Center (CEC) and advanced labs, with plans for further expansion. It will also showcase prototypes of upcoming MGI products, offering early access and testing opportunities for European partners and collaborators.

Customer Experience Center (CEC)

The CEC is equipped with MGI’s full product portfolio, serving as a dedicated hub for researchers and scientists to explore MGI’s cutting-edge life science innovations. Through tailored trainings, demos, and hands-on workflows, visitors can delve into the full potential of creating their own multi-omics tools based on MGI’s proprietary DNBSEQ™ technology. The G400 Developer Program, launched at the CEC opening, aims to support European researchers in developing customized workflows for spatial transcriptomics, multiplex immunofluorescence (mIF), and other multi-omics analyses.

Advanced Capabilities

The new facility boasts capabilities in DNA sequencing, Cell Omics, and Spatial Omics, positioning it to support novel applications and project development for MGI customers and collaborators.

Expanding Partnerships

MGI's expansion follows a stellar start to the year, marked by groundbreaking partnerships across Europe. In February, MGI collaborated with MetaGenoPolis in France, providing the DNBSEQ-T7 ultra-high throughput sequencer for the "Le French Gut" project and other research under the Million Microbiomes from Humans Project (MMHP).

In March, MGI partnered with Eurofins Genomics Europe Genotyping A/S, securing the first corporate order of the revolutionary DNBSEQ-T20×2 ultra-high throughput sequencer in Europe. This milestone paves the way for significant advancements in precision health initiatives across the continent.

Recently, MGI showcased its extensive lab automation and sequencing products at ECCMID 2024 and announced a technical assessment of the ABL DeepChek® assays by ABL Diagnostics on its DNBSEQ-G400 and DNBSEQ-G99 platforms. Further verification and validation studies of the DeepChek® assays will be conducted on the newly launched DNBSEQ-E25.

Future Prospects

“We have experienced positive growth and formed many valuable partnerships in the region in recent years. Establishing our new European headquarters will enable us to sustain this momentum to empower more users,” said Duncan Yu, President at MGI. “We look forward to witnessing further advancements by providing an optimal customer experience and facilitating collaboration for greater omics access and capabilities in Europe and globally.”

For more information about the G400 Developer Program, please visit here.